AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37847288
Drug: Soy supplementation
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy supplementation (60 g/d matched for protein and calories)
Trial: 37847317
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (4 g of omega-3 acid ethyl esters, Lovaza)
Trial: 37847518
Drug: 100-µg mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-µg mRNA-1273 (Moderna)
Trial: 37847518
Drug: 30-µg BNT162b2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-µg BNT162b2 (Pfizer-BioNTech)
Trial: 37847688
Drug: nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nintedanib 150 mg BID plus weekly docetaxel (35 mg/m2)
Trial: 37847688
Drug: nintedanib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nintedanib 200 mg BID plus weekly docetaxel (35 mg/m2)
Trial: 37847761
Drug: Epirubicin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (mean dose of 304 mg/m²)
Trial: 37847768
Drug: Other contemporary
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other contemporary therapies (primarily systemic thrombolysis and anticoagulation)
Trial: 37848259
Drug: Cosibelimab 800
RxNorm normalized name: Cosibelimab
DrugBank: Cosibelimab (DB15770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosibelimab 800 mg intravenously every 2 weeks
Trial: 37848297
Drug: Pyrvinium pamoate
RxNorm normalized name: Pyrvinium Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrvinium pamoate (PP) at 5 mg/kg orally for 3 days prior to surgery.
Trial: 37848297
Drug: Pyrvinium pamoate
RxNorm normalized name: Pyrvinium Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrvinium pamoate (PP) at 10 mg/kg orally for 3 days prior to surgery (if tolerated).
Trial: 37848297
Drug: Pyrvinium pamoate
RxNorm normalized name: Pyrvinium Pamoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrvinium pamoate (PP) at 20 mg/kg orally for 3 days prior to surgery (if tolerated).
Trial: 37848634
Drug: CS1-BCMA CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS1-BCMA CAR-T infusion
Trial: 37848887
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg immediate release methylphenidate (IR-MPH)
Trial: 37848908
Drug: MyoCare ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyoCare ophthalmic lenses
Trial: 37848908
Drug: Clearview ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearview ophthalmic lenses
Trial: 37849000
Drug: Transcutaneous auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous auricular vagus nerve stimulation (ta-VNS) targeting the cymba conchae of the external left ear, 5 min duration once daily for 2 weeks, followed by crossover to sham stimulation for 2 weeks, then ta-VNS 5 min duration twice daily until week 16.
Trial: 37849504
Drug: Clindamycin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin as adjunctive therapy
Trial: 37849628
Drug: Zagotenemab 70
RxNorm normalized name: Zagotenemab
DrugBank: Zagotenemab (DB16674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zagotenemab 70 mg
Trial: 37849628
Drug: Zagotenemab 210
RxNorm normalized name: Zagotenemab
DrugBank: Zagotenemab (DB16674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zagotenemab 210 mg
Trial: 37849628
Drug: Zagotenemab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zagotenemab (both doses)
Trial: 37849833
Drug: Non-invasive neuromodulation-induced
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive neuromodulation-induced cortical prehabilitation (NICP) protocol, involving 10 to 20 daily sessions of neuromodulation coupled with intensive task training.
Trial: 37850197
Drug: App-delivered cognitive-behavioral
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: App-delivered cognitive-behavioral therapy for insomnia (CBT-I) adjunct to inpatient multimodal rehabilitation
Trial: 37850330
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and ketamine infusions
Trial: 37850379
Drug: Inclisiran sodium
RxNorm normalized name: inclisiran sodium
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran sodium 300 mg (equivalent to 284 mg of inclisiran)
Trial: 37850941
Drug: Tubeless Automated
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tubeless Automated Insulin Delivery System
Trial: 37851284
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) oxygen therapy for 1 hour
Trial: 37851284
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy for 1 hour
Trial: 37851297
Drug: Sotatercept plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept plus background therapy (BGT)
Trial: 37851336
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral eliapixant twice daily
Trial: 37851412
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine (Shingrix)
Trial: 37851412
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine (Shingrix) in patients receiving JAKi + methotrexate
Trial: 37851500
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of eHealth solutions
Trial: 37851566
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg (DTG)
Trial: 37851566
Drug: Low-dose Efavirenz
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Efavirenz (EFV400)
Trial: 37851608
Drug: Single-dose rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose rituximab plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Trial: 37851608
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Trial: 37851663
Drug: Flunarizine (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (12-week treatment)
Trial: 37991122
Drug: New disabilities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New disabilities in instrumental activities of daily living
Trial: 37851874
Drug: Enzalutamide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group)
Trial: 37851874
Drug: Enzalutamide monotherapy
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide monotherapy (monotherapy group)
Trial: 37852261
Drug: Cadonilimab 6
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 6 mg/kg once every 2 weeks
Trial: 37852530
Drug: Recommended Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended Treatment of Obesity in Primary Care (RTOP)
Trial: 37852737
Drug: Nivolumab (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (480 mg) and metformin (1000 mg, orally, twice daily after a 14-day lead-in phase)
Trial: 37852774
Drug: MyCog paradigm
RxNorm normalized name: Mycogone nigra
DrugBank: Mycogone nigra (DB10971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MyCog paradigm (iPad-based, self-administered cognitive assessment)
Trial: 37853118
Drug: Oncolytic immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncolytic immunotherapy
Trial: 37853420
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (extracorporeal shockwave therapy + myofascial release therapy)
Trial: 37853454
Drug: H3K27M-vac vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H3K27M-vac vaccine administered with standard radiotherapy (RT) and atezolizumab (ATE)
Trial: 37853490
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein dose (≥ 2.2 g/kg body weight/day)
Trial: 37853490
Drug: Usual protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual protein dose (≤ 1.2 g/kg body weight/day)
Trial: 37853605
Drug: Intensive adherence
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive adherence counselling (IAC) - three once-monthly sessions
Trial: 37853676
Drug: 0.002% omidenepag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.002% omidenepag isopropyl (OMDI) once daily in both eyes for 3 months
Trial: 37855022
Drug: High-dose multimatrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose multimatrix mesalamine (1800-4800 mg)
Trial: 37855022
Drug: Low-dose multimatrix
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose multimatrix mesalamine (900-2400 mg)
Trial: 37855026
Drug: Inhaled interferon-β1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled interferon-β1a (SNG001) given once daily for 14 days
Trial: 37855227
Drug: Shortened course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened course of antibiotics
Trial: 37855227
Drug: Standard course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard course of antibiotics
Trial: 37855277
Drug: Online storytelling-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online storytelling-based acceptance and commitment therapy (ACT)
Trial: 37855448
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg subcutaneous injections monthly for 80 weeks)
Trial: 37856013
Drug: Alfosbuvir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfosbuvir plus Daclatasvir (600 mg alfosbuvir + 60 mg daclatasvir once daily for 12 weeks)
Trial: 37856106
Drug: Capecitabine (625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (625 mg/m2 orally twice daily for 21 days), Oxaliplatin (130 mg/m2 intravenously), Pembrolizumab (200 mg intravenously), with optional Epirubicin (50 mg/m2 every 3 weeks); followed by maintenance Pembrolizumab (14 additional doses).
Trial: 37856173
Drug: Sense2Quit App
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sense2Quit App with 8-week supply of nicotine replacement therapy, standard smoking cessation counseling, and access to the Sense2Quit mobile app and smartwatch
Trial: 37856182
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group A (treatment as usual)
Trial: 37856182
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group B (treatment as usual)
Trial: 37856199
Drug: VEGFR TKI
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGFR TKI therapy
Trial: 37856212
Drug: Maximal tumor
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal tumor debulking followed by systemic therapy
Trial: 37856386
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted hybrid version of the Incredible Years School Age Basic and Advance Programs delivered online, 12 weekly 2-hr sessions.
Trial: 37856920
Drug: 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/kg ARA and 50 mg/kg DHA supplementation
Trial: 37857068
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion of 500 mL of crystalloid solution
Trial: 37857147
Drug: Differential expression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differential expression of piRNAs in patients with hormonal treatment
Trial: 37857168
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 20 mg/kg after induction (n=300)
Trial: 37857496
Drug: Reduced HR
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced HR augmentation in OH participants
Trial: 37857620
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg ketamine
Trial: 37857710
Drug: Resistant potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant potato starch (RPS) daily from day -7 to day 100
Trial: 37857711
Drug: Tebotelimab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebotelimab monotherapy (600 mg once every 2 weeks)
Trial: 37857711
Drug: Tebotelimab in
RxNorm normalized name: Tebotelimab
DrugBank: Tebotelimab (DB16685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebotelimab in combination with margetuximab
Trial: 37857939
Drug: TXA administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA administered at the beginning of induction (TXAI)
Trial: 37857939
Drug: TXA administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA administered at the end of surgery (TXAP)
Trial: 37858005
Drug: Daridorexant 50
RxNorm normalized name: daridorexant 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg once daily
Trial: 37858007
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg Q4W
Trial: 37858007
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg Q2W
Trial: 37858132
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for OMD
Trial: 37858212
Drug: RPP group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPP group (low-dose and low-concentration iodine contrast medium)
Trial: 37858247
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) supplementation, 4 IU/day subcutaneous from the beginning of ovarian stimulation (OS) to the trigger day.
Trial: 37858328
Drug: Emicizumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emicizumab (6 and 3 mg/kg on days 1 and 2, 1·5 mg/kg weekly until week 12)
Trial: 37858585
Drug: Ad26.ZEBOV followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV followed by MVA-BN-Filo (Ebola vaccine group)
Trial: 37858585
Drug: Meningococcal quadrivalent
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal quadrivalent conjugate vaccine (control group)
Trial: 37858724
Drug: Maternal supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal supplement use during pregnancy
Trial: 37858867
Drug: Oral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral therapy after 3-5 days of IV therapy
Trial: 37859647
Drug: Narrow band
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow band green light (NbGL) treatment during migraine attacks
Trial: 37859748
Drug: Medium-dose ahaMSCs-Exos
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose ahaMSCs-Exos (intranasally administered two times per week for 12 weeks)
Trial: 37860863
Drug: Evinacumab 15
RxNorm normalized name: evinacumab 150 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Evkeeza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab 15 mg/kg every 4 weeks
Trial: 37861218
Drug: Tarlatamab 10
RxNorm normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab 10 mg every 2 weeks
Trial: 37861218
Drug: Tarlatamab 100
RxNorm normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab 100 mg every 2 weeks
Trial: 37861407
Drug: AGS15E at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS15E at 1.00 mg/kg
Trial: 37861407
Drug: AGS15E at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS15E at doses of ≥0.75 mg/kg
Trial: 37861407
Drug: AGS15E at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGS15E at doses of 0.50 to 1.25 mg/kg
Trial: 37861675
Drug: HBV active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV active drugs (HBV-ARV)
Trial: 37861988
Drug: Computer-Assisted Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-Assisted Cognitive Behavioral Therapy
Trial: 37862013
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg and Velpatasvir 100 mg for 12 weeks (2-week starter pack provided at diagnosis)
Trial: 37862013
Drug: Sofosbuvir-velpatasvir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir-velpatasvir treatment
Trial: 37862823
Drug: Oral omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral omega-3 fatty acids capsules (1 g daily)
Trial: 37862832
Drug: CANKADO-inform arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CANKADO-inform arm (drug intake documentation only)
Trial: 37863080
Drug: Rusfertide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rusfertide (10 mg once weekly for 24 weeks)
Trial: 37863084
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous insulin icodec
Trial: 37863158
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid prescription protocol (3-10 tablets of 5 mg oxycodone upon discharge)
Trial: 37863158
Drug: Restrictive opioid
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive opioid prescription protocol (no opioid prescription unless requested)
Trial: 37863158
Drug: Standard opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard opioid prescription protocol
Trial: 37863158
Drug: Restrictive opioid
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive opioid prescription protocol
Trial: 37863195
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg intrathecal morphine
Trial: 37863195
Drug: 150 mcg
RxNorm normalized name: kelp 150 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mcg intrathecal morphine
Trial: 37863195
Drug: 250 mcg
RxNorm normalized name: Nplate 250 MCG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg intrathecal morphine
Trial: 37863418
Drug: Oxygen reserve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen reserve index-guided oxygen titration
Trial: 37863418
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen titration based on pulse oximetry
Trial: 37863878
Drug: Laparoscopic TME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic TME with Denonvilliers' fascia preservation (L-DVF-P)
Trial: 37863878
Drug: Laparoscopic TME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic TME with Denonvilliers' fascia resection (L-DVF-R)
Trial: 37863916
Drug: Camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab (200 mg on day 1) plus nab-paclitaxel (125 mg/m2) and epirubicin (dosage not specified)
Trial: 37864049
Drug: Nimotuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab plus concurrent chemo-radiotherapy (CCRT)
Trial: 37864049
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus concurrent chemo-radiotherapy (CCRT)
Trial: 37864152
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiation therapy (SABR) in addition to standard of care (Arm 2)
Trial: 37864152
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care therapy (Arm 1)
Trial: 37864252
Drug: Immersive virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive virtual reality (VR) therapy through an immersive VR garden intervention